Short Interest in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Grows By 93.6%

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 1,500,000 shares, an increase of 93.6% from the November 15th total of 774,700 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average daily volume of 16,110,000 shares, the short-interest ratio is presently 0.1 days.

Tevogen Bio Stock Down 1.0 %

Shares of NASDAQ TVGN traded down $0.01 during midday trading on Friday, reaching $1.00. The company’s stock had a trading volume of 859,211 shares, compared to its average volume of 4,787,343. The business’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $0.91. Tevogen Bio has a fifty-two week low of $0.26 and a fifty-two week high of $21.09.

Insider Transactions at Tevogen Bio

In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of the business’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $1.62, for a total value of $1,747,332.00. Following the completion of the sale, the insider now owns 4,254,302 shares of the company’s stock, valued at $6,891,969.24. The trade was a 20.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 56.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. HGC Investment Management Inc. purchased a new position in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 223,077 shares of the company’s stock, valued at approximately $82,000. HGC Investment Management Inc. owned 0.13% of Tevogen Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.